Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

cryptococcosis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

cryptococcosis

MONDO:0005724

Also known as:Busse-Buschke's diseaseCryptococcal infectionCryptococcus neoformans caused disease or disorder

Find Clinical TrialsTrials

Overview

An acute or chronic, localized or disseminated infection by Cryptococcus neoformans. Sites of involvement include the lungs, central nervous system and meninges, skin, and visceral organs.--2004

Treatments1 FDA approved

Clinical Trials2 registered · 2 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include common findings: Fever, Immunodeficiency, Cough, and Nodular pattern on pulmonary HRCT; and sometimes findings: Hydrocephalus, Abnormality of the eye, Abnormality of vision, and Atypical behavior and others. 42 total HPO annotations.

Organ System	Phenotype Count	Example Features
Brain and nerves	11	Hydrocephalus, Atypical behavior, Mental deterioration

Diagnosis

Biomarker and diagnostic research for cryptococcosis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for cryptococcosis, including FLUCYTOSINE (ANCOBON, approved 1971). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Phenotype severity distribution: 4 common features.

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

2 clinical trials registered, 2 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.

381 publications have been identified in PubMed for cryptococcosis. Kisho has analyzed 265 by research type. Research spans Basic Science / Preclinical (28%), Review / Meta-Analysis (20%), and Case Report / Case Series (18%).

Research Type	Count	% of Total
Laboratory research	74

Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 12:35 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:1546

GARD

Genetic and Rare Diseases Info Center

GARD:6218

Questions for Your Care Team

→What are the benefits and potential side effects of ANCOBON for managing cryptococcosis?
→Are any of the 2 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Encochleated oral Amphotericin B suspension	Encochleated oral Amphotericin B suspension	Matinas BioPharma Nanobiotechnologies, Inc.	2019	—	Designated
fosmanogepix	fosmanogepix	Basilea Pharmaceutica Ltd, Allschwil	2019	—	Designated

Kisho

cryptococcosis

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Isolated Hepatic Cryptococcosis in an Immunocompetent Child: A Rare Cause of Granulomatous Hepatitis with Cholestasis.

Intralobar pulmonary sequestration coexisting with pulmonary cryptococcosis: A case report and literature review.

Cases Of Recreational Water Illnesses On The Rise

cryptococcosis

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Isolated Hepatic Cryptococcosis in an Immunocompetent Child: A Rare Cause of Granulomatous Hepatitis with Cholestasis.

Intralobar pulmonary sequestration coexisting with pulmonary cryptococcosis: A case report and literature review.

Cases Of Recreational Water Illnesses On The Rise